CHAI’s work in the African Vaccine Manufacturing (AVM) space has been targeted at achieving a fit-for-purpose, sustainable vaccine manufacturing footprint. These publications represent some of the work CHAI has undertaken at the ecosystem level, informed by work with individual manufacturers and governments, to ensure that the vaccine landscape becomes more pandemic prepared, achieves greater security of vaccine supply, and promotes economic viability for vaccine manufacturing projects.
This white paper examines the opportunities and challenges for new manufacturers aiming to build globally competitive and commercially viable businesses in the low- and middle-income country vaccine markets.
PATH and CHAI share the results of their updated study of Africa’s vaccine manufacturing landscape at the DCVMN 2024 annual general meeting.
In this whitepaper, we outline a continental market-shaping strategy for a sustainable vaccine manufacturing footprint in Africa to improve health outcomes and save lives.
The Africa CDC, CHAI, and PATH have released a briefing paper, “Current and planned vaccine manufacturing in Africa,” following an assessment of vaccine manufacturing capacity in Africa
This study of Africa’s current and planned vaccine manufacturing capacity offers insights into how to target investments and development efforts to promote long-term success.
Results from a joint assessment by Africa CDC, CHAI, and PATH of current and planned vaccine manufacturing in Africa.
An analysis of the rapidly evolving African vaccine manufacturing ecosystem using publicly available data to identify patterns in current manufacturing capacity, plans for scale-up, and opportunities and challenges facing the sector.
The database offers insights into donor and political commitments and tech-transfers to increase local manufacturing capacity in low- and middle-income countries to respond to global Covid-19 vaccine inequity
